Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.8M | $71.6M | $59.5M | $57.5M | $100M | $37.3M | $53.2M | $101M | $138M | $76.2M |
| Revenue growth | — | 457.6% | -16.9% | -3.4% | 74.6% | -62.8% | 42.5% | 90.4% | 36.4% | -44.8% |
| Operating income | -$59.6M | -$46.3M | -$77.9M | -$111M | -$48.6M | -$116M | -$101M | -$6.48M | $25.0M | -$22.4M |
| Operating margin | -463.9% | -64.6% | -130.9% | -192.9% | -48.4% | -311.0% | -190.6% | -6.4% | 18.1% | -29.3% |
| Net income | -$58.9M | -$43.1M | -$84.6M | -$102M | -$32.9M | -$116M | -$99.3M | -$569K | $31.9M | -$17.4M |
| Net margin | -458.5% | -60.2% | -142.2% | -177.8% | -32.8% | -310.5% | -186.8% | -0.6% | 23.1% | -22.8% |
| EPS (diluted) | -$1.63 | -$1.16 | — | — | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.03M | $170M | -$75.5M | -$140M | $5.26M | -$119M | -$111M | -$56.0M | -$86.2M | -$75.6M |
| Capital expenditures | $2.18M | $1.56M | $3.79M | $3.50M | $2.31M | $1.61M | $1.74M | $840K | $310K | $220K |
| Free cash flow | -$4.21M | $169M | -$79.3M | -$144M | $2.95M | -$121M | -$113M | -$56.9M | -$86.5M | -$75.8M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $105M | $178M | $248M | $188M | $192M | $206M | $194M | $17.2M | $38.1M | $12.7M |
| Total assets | $199M | $398M | $457M | $341M | $359M | $339M | $261M | $202M | $121M | $152M |
| Total liabilities | $121M | $328M | $326M | $290M | $309M | $340M | $347M | $249M | $121M | $52.6M |
| Shareholders' equity | $78.5M | $69.9M | $131M | $51.1M | -$7.77M | -$459K | -$85.8M | -$47.4M | -$456K | $99.0M |
| Retained earnings | -$176M | -$219M | -$315M | -$417M | -$450M | -$624M | -$723M | -$723M | -$692M | -$712M |
| Shares (wtd avg diluted) | 36.5M | 38.5M | 45.1M | 45.5M | 48.3M | 64.1M | 65.7M | 73.8M | 84.7M | 138M |
Every figure is extracted from CytomX Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.